Sensei biotherapeutics reports second quarter 2024 financial results and recent business highlights

- promising phase 1/2 sns-101 clinical data presented at asco 2024 - - enrollment in the phase 1 dose expansion of sns-101 clinical trial advancing with initial data on track for q4 2024 - - strong balance sheet with cash runway into the fourth quarter of 2025 - boston, aug. 06, 2024 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter ended june 30, 2024, and provided corporate updates. “collectively, the clinical data presented on sns-101 over the past six months demonstrated early signs of clinical activity in a patient population generally resistant to immunotherapy, a well-tolerated safety profile, and the avoidance of a pharmacokinetic sink that hindered first-generation approaches to targeting vista,” said john celebi, president and chief executive officer.
SNSE Ratings Summary
SNSE Quant Ranking